HCE方案治疗常规方案失效的非小细胞肺癌156例分析

目的：探讨羟基喜树碱（ＨＣＰＴ）、卡铂（ＣＢＰ）和足叶乙甙（ＶＰ－１６）联合治疗常规方案（ＭＶＰ）失效的晚期非小细胞肺癌的疗效。方法：１５６例晚期非小细胞肺癌患者接受常规方案２￣４周期治疗失效后改用ＨＣＰＴ＋ＣＢＴ＋ＶＰ－１６（ＨＣＥ）化疗：ＨＣＰＴ ６ｍｇ／ｍ＾２，ｉｖ，ｄｌ￣５；ＣＢＰ ３００ｍｇ／ｍ＾２，ｉｖ，ｄｌ；ＶＰ－１６ １００ｍｇ，ｉｖ，ｄｌ￣５。２８天为１周期，每例用药２周期。观察

Treatment of HCE Regimen for Refractory Non-Small Cell Lung Cancer(A Report of 156 Cases)

PurposeTo evaluate the efficacy of hydroxycamptothecin (HCPT)， carboplatin (CBP) and Etoposide (VP16) combination in treating advanced non－small cell lung cancer(NSCLC)which failed to respond to MVP regimen． MethodsOne hundred fifty－six patients received HCPT，CBP and VP16 (HCE) chemotherapyHCPT 6mg／m2 iv d1～5 CBP 300mg／m2 iv gtt d1 VP16 100mg iv gtt d1～5． Every case was given two circles． ResultsAfter two circles of chemotherapy， the response rate was 44．8％ in squamous cell carcinoma and 38．3％ in adenocarcinoma， the overall response rate was 42．3％． The major toxicity was leukopenia and gastrointestinal reaction． ConclusionHCE regimen has high efficacy in refractory non－small cell lung cancer， it may especially be recommended using in recurrent cases．